Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases

Am J Hematol. 2015 Aug;90(8):E146-8. doi: 10.1002/ajh.24045. Epub 2015 May 28.

Authors

Zi Chen^{1

2}, Wei Wang¹, Amy Rich¹, Guilin Tang¹, Shimin Hu¹

Affiliations

¹ Department of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
² Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China.

PMID: 25960187
DOI: 10.1002/ajh.24045

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Aged
Antineoplastic Agents / therapeutic use*
Boronic Acids / therapeutic use*
Bortezomib
Female
Humans
Karyotyping
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
Male
Melphalan / therapeutic use
Middle Aged
Multiple Myeloma / complications*
Multiple Myeloma / drug therapy
Multiple Myeloma / genetics
Multiple Myeloma / mortality
Prednisone / therapeutic use
Prognosis
Protein Kinase Inhibitors / therapeutic use*
Pyrazines / therapeutic use*
Sarcoma, Myeloid / complications*
Sarcoma, Myeloid / drug therapy
Sarcoma, Myeloid / genetics
Sarcoma, Myeloid / mortality
Survival Analysis

Substances

Antineoplastic Agents
Boronic Acids
Protein Kinase Inhibitors
Pyrazines
Bortezomib
Melphalan
Prednisone